"Why would carter work for free???"
What kind of work does Carter do now? Not one thing I'm guessing. He is 80 and probably spends his day taking quite a few naps.
Why wouldn't HEB be presenting at ASCO if all these "Noble Prize Winner work with Ampligen" cancer trials going on?
Carter sleep through it and not show up like he did the conference last week?
It's already been 20 since revenue, the drugs are 40 years old. The CEO is at least 80.
How much more time does a company need?
In MICE. When does the human trials start? Never is my guess. Just like everything else HEB's says it's drugs are good for.
Never one tested in Humans for any of these indications. Why is that? I think it's because Carter wants to conserve cash to pay himself and bonus money.
Yep! HEB is the stock if you would like a tax break on your taxes next year from a loss.
Read the 10k's, the company is about funding the CEO's lifestyle rather than clinical development.
CEO takes 5% in CASH as a bonus from all newly issued stock sales.
CEO had HEB paying for his vacation home.
Company has no revenue in 20 years, drug are 40 years old, CEO pays himself 1.000.000 a year +
MFG facility has been "Under upgrades" since 2008 and is always "18 months out from completion".
in the next 2 months, not sure. CLDX MAY get accelerated approval for one of their drugs within that time frame (recently got break thru designation and it's in Phase 2 trials, newly diagnosed is in phase 3 ). If they do the stock will go to 40 + overnight. 40/60 chance of that happening. Interim results of phase 3 to come out this summer and a 40//60 chance it gets halted for efficacy. Stock will shot to 60 if that happens.
Come July, ESPR will have results in blood pressure for their cholesterol drug (CEO developed Lipitor, the biggest selling drug ever). If the BP results from the investigational study come out positive, the stock has at least 50% upside as it will be the only cholesterol drug that lowers BP as a side effect. Still a ways out from FDA approval, but probably will get bought out long before it goes to the FDA. IMO.
Hum. You mean the report that HEB paid for?
And exactly how is that going to happen? The genital wart market isn't that big and it's main competitor is a $70 cream. HEB has no other drug that they can sell and reoccurring genital warts is the only insurance covered use for Alferon. So it's not even the first choice of treatment.
Also, the last year of Alferon sales had fewer than 500 scripts. It's very difficult for me to see any type of significant sales.
Please advise on how HEB is going to generate 100 million in sales of it's wonder drugs.
That is some great investing advice! Never mind business fundamentals or that the CEO dumped 21 million shares on the market last quarter AND took 5% off the top as a "bonus".
Also, the company hasn't had ANY significant revenue in 20+ years.
So what's with YOUR posts saying some company is "upgrading the MFG plant".
So it's already operational? Is that what you are saying? HEB can make Alferon TODAY?
Anyone think they will give it nod prior to long term study results or for the cognitive impairment they seem to cause?
Not sure how this will play out, I think the FDA is largely a "pay for approval" with big pharma but I think there is a possibility of a request for an additional trial to address cognitive impairment because of the large market this addresses. If PCSK9 is postponed, ESPR is looking way better.
Anyone else has some insight on this?
Since Bones or whoever he is today is claiming that an Analyst that HEB paid for is projecting 100 million in sales from a company with 40 year old drugs, no significant revenue in 20 + years and 1 FDA approved indication for Genital Warts is going to get to 100 million in sales?
I'm just wondering how many scripts are needed to generate 100 million in sales? Keep in mind that there is a topical cream for $70 bucks VS being jabbed by a needle bearing Alferon.
Can anyone calculate what it's going to take to get to 100 million in sales? How many scripts will need to be filled and at what price this magic elixir is needed?
Can anyone clarify this for me? I read the Analyst report that HEB paid for, they gave a projection but didn't say ONE THING on HOW HEB is going to generate this revenue.
What kind of analysis is this?
"interferon market in USA is 5bil. alferon is the best natural approved interferon"
Okay, not sure how true the 5 billion number is but say that is true.
HEB's Alferon is ONLY FDA approved for Recurring Genital Warts. So, Insurance claims will only be paid for Genital Warts when Alferon is used.
Any other indication that HEB's Alferon will be used for will be out of pocket. I doubt anyone is going to pay out of pocket for HEB's Alferon when others are available and covered under insurance.
If HEB wants other indications for their superior Alferon, they will have to do clinical trials, submit results to the FDA and go through the approval process if they want insurance reimbursement.
I think everyone knows how HEB and Carter feels about spending money to do any more clinical trials. Won't happen.
Again, I don't see where 100 million is coming from.
"Sure...just as sure as you show how you know heb paid...."
I can read. It CLEARLY states that in the report. Very clearly. I guess you missed that. Much like you miss all the other great info in the 10k's. Like 5% bonus on the sale of newly issued stock, company paid vacation homes, the MFG plant upgrades being 18 months out now for 7 years.
Do you just blindly invest in companies hoping they know what they are doing?
You don't know how drug approvals work? I'm surprised by that. You really should do more DD before investing in BIO companies.
Why don't you post the ENTIRE paragraph instead of picking just the part you like.
And just so you know the "Company" is addressed as Hemispherx Biopharma
Arrowhead BID will
be receiving fees in 2015 from the Company for a series
of investor relations and information dissemination
services, including distribution of this report. In the next
three months, the partners at Arrowhead BID expect to
receive, or intend to seek, a mandate for investment
banking services from the Company.
You also must have missed this key paragraph as well, from the same report.
"Inadequate financial resources/Delay in Commercialization: Inadequate financial resources to perform time consuming research, preclinical development, clinical trials and other procedures required to commercialize and market products remains a significant risk. Cash and cash equivalent stood at $17.4MM as of September 30, 2014,However, inability to commercialize and sell Ampligen® or Alferon® LDO and/or recommence material sales of Alferon N Injection® would put significant pressure on the Company’s operational, financial and liquidity position"